Symbiotic formulation in experimentally induced liver fibrosis in rats: intestinal microbiota as a key point to treat liver damage?
Aim Evidence indicates that intestinal microbiota may participate in both the induction and the progression of liver damage. The aim of our research was the detection and evaluation of the effects of chronic treatment with a symbiotic formulation on CCl4‐induced rat liver fibrosis. Results CCl4 sign...
Saved in:
Published in | Liver international Vol. 33; no. 5; pp. 687 - 697 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Blackwell Publishing Ltd
01.05.2013
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Aim
Evidence indicates that intestinal microbiota may participate in both the induction and the progression of liver damage. The aim of our research was the detection and evaluation of the effects of chronic treatment with a symbiotic formulation on CCl4‐induced rat liver fibrosis.
Results
CCl4 significantly increased gastric permeability in respect to basal values, and the treatment with symbiotic significantly decreased it. CCl4 per se induced a decrease in intestinal permeability. This effect was also seen in fibrotic rats treated with symbiotic and was still evident when normal rats were treated with symbiotic alone (P < 0.001 in all cases). Circulating levels of pro‐inflammatory cytokine TNF‐α were significantly increased in rats with liver fibrosis as compared with normal rats, while symbiotic treatment normalized the plasma levels of TNF‐α and significantly enhanced anti‐inflammatory cytokine IL 10. TNF‐α, TGF‐β, TLR4, TLR2, iNOS and α‐SMA mRNA expression in the liver were up‐regulated in rats with CCl4‐induced liver fibrosis and down‐regulated by symbiotic treatment. Moreover, IL‐10 and eNOS mRNA levels were increased in the CCL4+symbiotic group. Symbiotic treatment of fibrotic rats normalized serum ALT, AST and improved histology and liver collagen deposition. DGGE analysis of faecal samples revealed that CCl4 administration and symbiotic treatment either alone or in combination produced modifications in faecal profiles vs controls.
Conclusions
Our results provide evidence that in CCl4‐induced liver fibrosis, significant changes in gastro‐intestinal permeability and in faecal flora occur. Treatment with a specific symbiotic formulation significantly affects these changes, leading to improvement in both liver inflammation and fibrosis. |
---|---|
AbstractList | Evidence indicates that intestinal microbiota may participate in both the induction and the progression of liver damage. The aim of our research was the detection and evaluation of the effects of chronic treatment with a symbiotic formulation on CCl4-induced rat liver fibrosis. CCl4significantly increased gastric permeability in respect to basal values, and the treatment with symbiotic significantly decreased it. CCl4per se induced a decrease in intestinal permeability. This effect was also seen in fibrotic rats treated with symbiotic and was still evident when normal rats were treated with symbiotic alone (P <0.001 in all cases). Circulating levels of pro-inflammatory cytokine TNF- alpha were significantly increased in rats with liver fibrosis as compared with normal rats, while symbiotic treatment normalized the plasma levels of TNF- alpha and significantly enhanced anti-inflammatory cytokine IL 10. TNF- alpha , TGF- beta , TLR4, TLR2, iNOS and alpha -SMA mRNA expression in the liver were up-regulated in rats with CCl4-induced liver fibrosis and down-regulated by symbiotic treatment. Moreover, IL-10 and eNOS mRNA levels were increased in the CCL4+symbiotic group. Symbiotic treatment of fibrotic rats normalized serum ALT, AST and improved histology and liver collagen deposition. DGGE analysis of faecal samples revealed that CCl4 administration and symbiotic treatment either alone or in combination produced modifications in faecal profiles vs controls. Our results provide evidence that in CCl4-induced liver fibrosis, significant changes in gastro-intestinal permeability and in faecal flora occur. Treatment with a specific symbiotic formulation significantly affects these changes, leading to improvement in both liver inflammation and fibrosis. Evidence indicates that intestinal microbiota may participate in both the induction and the progression of liver damage. The aim of our research was the detection and evaluation of the effects of chronic treatment with a symbiotic formulation on CCl4 -induced rat liver fibrosis. CCl4 significantly increased gastric permeability in respect to basal values, and the treatment with symbiotic significantly decreased it. CCl4 per se induced a decrease in intestinal permeability. This effect was also seen in fibrotic rats treated with symbiotic and was still evident when normal rats were treated with symbiotic alone (P < 0.001 in all cases). Circulating levels of pro-inflammatory cytokine TNF-α were significantly increased in rats with liver fibrosis as compared with normal rats, while symbiotic treatment normalized the plasma levels of TNF-α and significantly enhanced anti-inflammatory cytokine IL 10. TNF-α, TGF-β, TLR4, TLR2, iNOS and α-SMA mRNA expression in the liver were up-regulated in rats with CCl4 -induced liver fibrosis and down-regulated by symbiotic treatment. Moreover, IL-10 and eNOS mRNA levels were increased in the CCL4 (+) symbiotic group. Symbiotic treatment of fibrotic rats normalized serum ALT, AST and improved histology and liver collagen deposition. DGGE analysis of faecal samples revealed that CCl4 administration and symbiotic treatment either alone or in combination produced modifications in faecal profiles vs controls. Our results provide evidence that in CCl4 -induced liver fibrosis, significant changes in gastro-intestinal permeability and in faecal flora occur. Treatment with a specific symbiotic formulation significantly affects these changes, leading to improvement in both liver inflammation and fibrosis. Evidence indicates that intestinal microbiota may participate in both the induction and the progression of liver damage. The aim of our research was the detection and evaluation of the effects of chronic treatment with a symbiotic formulation on CCl4 -induced rat liver fibrosis.AIMEvidence indicates that intestinal microbiota may participate in both the induction and the progression of liver damage. The aim of our research was the detection and evaluation of the effects of chronic treatment with a symbiotic formulation on CCl4 -induced rat liver fibrosis.CCl4 significantly increased gastric permeability in respect to basal values, and the treatment with symbiotic significantly decreased it. CCl4 per se induced a decrease in intestinal permeability. This effect was also seen in fibrotic rats treated with symbiotic and was still evident when normal rats were treated with symbiotic alone (P < 0.001 in all cases). Circulating levels of pro-inflammatory cytokine TNF-α were significantly increased in rats with liver fibrosis as compared with normal rats, while symbiotic treatment normalized the plasma levels of TNF-α and significantly enhanced anti-inflammatory cytokine IL 10. TNF-α, TGF-β, TLR4, TLR2, iNOS and α-SMA mRNA expression in the liver were up-regulated in rats with CCl4 -induced liver fibrosis and down-regulated by symbiotic treatment. Moreover, IL-10 and eNOS mRNA levels were increased in the CCL4 (+) symbiotic group. Symbiotic treatment of fibrotic rats normalized serum ALT, AST and improved histology and liver collagen deposition. DGGE analysis of faecal samples revealed that CCl4 administration and symbiotic treatment either alone or in combination produced modifications in faecal profiles vs controls.RESULTSCCl4 significantly increased gastric permeability in respect to basal values, and the treatment with symbiotic significantly decreased it. CCl4 per se induced a decrease in intestinal permeability. This effect was also seen in fibrotic rats treated with symbiotic and was still evident when normal rats were treated with symbiotic alone (P < 0.001 in all cases). Circulating levels of pro-inflammatory cytokine TNF-α were significantly increased in rats with liver fibrosis as compared with normal rats, while symbiotic treatment normalized the plasma levels of TNF-α and significantly enhanced anti-inflammatory cytokine IL 10. TNF-α, TGF-β, TLR4, TLR2, iNOS and α-SMA mRNA expression in the liver were up-regulated in rats with CCl4 -induced liver fibrosis and down-regulated by symbiotic treatment. Moreover, IL-10 and eNOS mRNA levels were increased in the CCL4 (+) symbiotic group. Symbiotic treatment of fibrotic rats normalized serum ALT, AST and improved histology and liver collagen deposition. DGGE analysis of faecal samples revealed that CCl4 administration and symbiotic treatment either alone or in combination produced modifications in faecal profiles vs controls.Our results provide evidence that in CCl4 -induced liver fibrosis, significant changes in gastro-intestinal permeability and in faecal flora occur. Treatment with a specific symbiotic formulation significantly affects these changes, leading to improvement in both liver inflammation and fibrosis.CONCLUSIONSOur results provide evidence that in CCl4 -induced liver fibrosis, significant changes in gastro-intestinal permeability and in faecal flora occur. Treatment with a specific symbiotic formulation significantly affects these changes, leading to improvement in both liver inflammation and fibrosis. Aim Evidence indicates that intestinal microbiota may participate in both the induction and the progression of liver damage. The aim of our research was the detection and evaluation of the effects of chronic treatment with a symbiotic formulation on CCl4‐induced rat liver fibrosis. Results CCl4 significantly increased gastric permeability in respect to basal values, and the treatment with symbiotic significantly decreased it. CCl4 per se induced a decrease in intestinal permeability. This effect was also seen in fibrotic rats treated with symbiotic and was still evident when normal rats were treated with symbiotic alone (P < 0.001 in all cases). Circulating levels of pro‐inflammatory cytokine TNF‐α were significantly increased in rats with liver fibrosis as compared with normal rats, while symbiotic treatment normalized the plasma levels of TNF‐α and significantly enhanced anti‐inflammatory cytokine IL 10. TNF‐α, TGF‐β, TLR4, TLR2, iNOS and α‐SMA mRNA expression in the liver were up‐regulated in rats with CCl4‐induced liver fibrosis and down‐regulated by symbiotic treatment. Moreover, IL‐10 and eNOS mRNA levels were increased in the CCL4+symbiotic group. Symbiotic treatment of fibrotic rats normalized serum ALT, AST and improved histology and liver collagen deposition. DGGE analysis of faecal samples revealed that CCl4 administration and symbiotic treatment either alone or in combination produced modifications in faecal profiles vs controls. Conclusions Our results provide evidence that in CCl4‐induced liver fibrosis, significant changes in gastro‐intestinal permeability and in faecal flora occur. Treatment with a specific symbiotic formulation significantly affects these changes, leading to improvement in both liver inflammation and fibrosis. |
Author | Federico, Alessandro Morelli, Lorenzo Chirico, Marilena Mazzone, Giovanna Loguercio, Carmela D'Argenio, Giuseppe Romano, Marco Cariello, Rita Callegari, Maria L. Grossi, Enzo Funaro, Annalisa Caporaso, Nicola De Magistris, Laura Tuccillo, Concetta |
Author_xml | – sequence: 1 givenname: Giuseppe surname: D'Argenio fullname: D'Argenio, Giuseppe email: dargenio@unina.it organization: Gastroenterologia, Università Federico II, Napoli, Italy – sequence: 2 givenname: Rita surname: Cariello fullname: Cariello, Rita organization: Centro Interuniversitario Ricerche su Alimenti, Nutrizione e Apparato Digerente (CIRANAD), Napoli, Italy – sequence: 3 givenname: Concetta surname: Tuccillo fullname: Tuccillo, Concetta organization: Centro Interuniversitario Ricerche su Alimenti, Nutrizione e Apparato Digerente (CIRANAD), Napoli, Italy – sequence: 4 givenname: Giovanna surname: Mazzone fullname: Mazzone, Giovanna organization: Gastroenterologia, Università Federico II, Napoli, Italy – sequence: 5 givenname: Alessandro surname: Federico fullname: Federico, Alessandro organization: Centro Interuniversitario Ricerche su Alimenti, Nutrizione e Apparato Digerente (CIRANAD), Napoli, Italy – sequence: 6 givenname: Annalisa surname: Funaro fullname: Funaro, Annalisa organization: Gastroenterologia, Seconda Università di Napoli, Napoli, Italy – sequence: 7 givenname: Laura surname: De Magistris fullname: De Magistris, Laura organization: Centro Interuniversitario Ricerche su Alimenti, Nutrizione e Apparato Digerente (CIRANAD), Napoli, Italy – sequence: 8 givenname: Enzo surname: Grossi fullname: Grossi, Enzo organization: Bracco Spa, Milan, Italy – sequence: 9 givenname: Maria L. surname: Callegari fullname: Callegari, Maria L. organization: Centro Ricerche Biotecnologiche, Università Cattolica del Sacro Cuore, Cremona, Italy – sequence: 10 givenname: Marilena surname: Chirico fullname: Chirico, Marilena organization: Gastroenterologia, Seconda Università di Napoli, Napoli, Italy – sequence: 11 givenname: Nicola surname: Caporaso fullname: Caporaso, Nicola organization: Gastroenterologia, Università Federico II, Napoli, Italy – sequence: 12 givenname: Marco surname: Romano fullname: Romano, Marco organization: Centro Interuniversitario Ricerche su Alimenti, Nutrizione e Apparato Digerente (CIRANAD), Napoli, Italy – sequence: 13 givenname: Lorenzo surname: Morelli fullname: Morelli, Lorenzo organization: Istituto di Microbiologia, Università Cattolica del Sacro Cuore, Piacenza, Italy – sequence: 14 givenname: Carmela surname: Loguercio fullname: Loguercio, Carmela organization: Centro Interuniversitario Ricerche su Alimenti, Nutrizione e Apparato Digerente (CIRANAD), Napoli, Italy |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23448378$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkU9vFCEYh4mpsX_04BcwHPUwLQwsDF5MbWqt2WiMWo-EYd4xWGZYgbGds19ctrvbg9HIBUKe3w_yvIdobwwjIPSUkmNa1ol3P49pTal8gA4ol03Fakb37s8120eHKX0nhCq1oI_Qfs04b5hsDtCvT_PQupCdxX2Iw-RNdmHEbsRwu4LoBhiz8X4uN91kocPlLYi4d20MyaU1GE1OL8shQ8puNB4PzsawLjXYJGzwNcx4FQqAc8A5gsnbls4M5hu8eowe9sYneLLdj9CXN-efz95Wyw8Xl2eny8pyUctKtaIjQDjpGsUNIY1oiWINU40QjHU9AeAth1opaY1tbCdsTynrwS5433LDjtDzTe8qhh9T-a0eXLLgvRkhTElTobiSTC3U_1FWcyWKcVbQZ1t0agfo9KpIM3HWO8cFONkAxUpKEXptXb7TnKNxXlOi11PUxYm-m2JJvPgjsSv9G7ttv3Ee5n-Denl5tUtUm4RLGW7vEyZeayGZXOiv7y_0a3UlueIf9Tv2GwuXvHI |
CitedBy_id | crossref_primary_10_1007_s11356_018_3197_2 crossref_primary_10_1111_cbdd_14241 crossref_primary_10_3390_foods10061386 crossref_primary_10_1016_j_bpg_2016_02_004 crossref_primary_10_1097_MOG_0000000000000326 crossref_primary_10_1007_s10753_014_0019_7 crossref_primary_10_3390_ijms26072997 crossref_primary_10_1038_s41598_017_07278_6 crossref_primary_10_1002_cbin_10699 crossref_primary_10_1111_liv_12566 crossref_primary_10_1016_j_jnutbio_2015_11_008 crossref_primary_10_1039_D0FO00711K crossref_primary_10_1371_journal_pone_0178684 crossref_primary_10_1517_14728222_2014_885953 crossref_primary_10_17816_brmma25933 crossref_primary_10_1016_j_ijfoodmicro_2015_04_029 crossref_primary_10_1152_ajpgi_00023_2017 crossref_primary_10_1155_2016_4694726 crossref_primary_10_1155_2017_5801768 crossref_primary_10_3748_wjg_v20_i42_15632 crossref_primary_10_1186_s13020_022_00607_6 crossref_primary_10_1016_j_fitote_2023_105653 crossref_primary_10_1038_s41598_017_07091_1 crossref_primary_10_2478_ii_2018_0027 |
Cites_doi | 10.1016/j.ijfoodmicro.2004.04.020 10.1002/hep.24018 10.1016/S1570-0232(02)00766-3 10.1111/j.1530-0277.2009.01022.x 10.1016/j.dld.2010.10.015 10.1007/s10620-007-0184-8 10.3748/wjg.v12.i10.1493 10.1097/01.mpg.0000226379.41365.62 10.1056/NEJMe1000850 10.1590/S0004-28032010000200014 10.1046/j.1440-1746.2000.2340.x 10.1258/002367791780808158 10.1371/journal.pone.0023035 10.1016/S1665-2681(19)31866-6 10.3109/00365521.2011.574730 10.1016/j.bmcl.2004.01.107 10.1111/j.1530-0277.2010.01399.x 10.1016/S0168-8278(02)00142-3 10.1152/ajpgi.00243.2009 10.2174/092986711796391679 10.1002/hep.21097 10.1128/AEM.66.1.297-303.2000 10.1371/journal.pone.0023037 10.1097/MOG.0b013e32833f1222 10.1016/j.dld.2006.07.010 10.1097/01.mcg.0000165671.25272.0f 10.1152/ajpgi.00188.2010 10.1016/j.dld.2009.05.001 10.1002/hep.22711 10.1002/hep.22848 10.3109/03639045.2010.527348 10.1111/j.1572-0241.2002.05942.x |
ContentType | Journal Article |
Copyright | 2013 John Wiley & Sons A/S 2013 John Wiley & Sons A/S. |
Copyright_xml | – notice: 2013 John Wiley & Sons A/S – notice: 2013 John Wiley & Sons A/S. |
DBID | BSCLL AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7T7 8FD C1K FR3 P64 |
DOI | 10.1111/liv.12117 |
DatabaseName | Istex CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Industrial and Applied Microbiology Abstracts (Microbiology A) Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database Biotechnology and BioEngineering Abstracts |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Engineering Research Database Technology Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management |
DatabaseTitleList | Engineering Research Database MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
EISSN | 1478-3231 |
EndPage | 697 |
ExternalDocumentID | 23448378 10_1111_liv_12117 LIV12117 ark_67375_WNG_B9V7494Q_J |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Bracco Spa funderid: BR720c |
GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OC 29L 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAKAS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZCM ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K ROL RX1 SUPJJ SV3 TEORI TUS UB1 W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR X7M XG1 ZXP ZZTAW ~IA ~WT AAHQN AAIPD AAMNL AANHP AAYCA ACRPL ACUHS ACYXJ ADNMO AFWVQ ALVPJ AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY CGR CUY CVF ECM EIF NPM 7X8 1OB 7T7 8FD C1K FR3 P64 |
ID | FETCH-LOGICAL-c4627-9b6d0e040d894a0086b09383986633df0ee4b4e2997cac8cd6cf113fec54fb4a3 |
IEDL.DBID | DR2 |
ISSN | 1478-3223 1478-3231 |
IngestDate | Tue Aug 05 10:39:22 EDT 2025 Fri Jul 11 08:41:49 EDT 2025 Mon Jul 21 06:04:54 EDT 2025 Thu Apr 24 23:09:12 EDT 2025 Tue Jul 01 04:09:57 EDT 2025 Wed Jan 22 17:00:02 EST 2025 Wed Oct 30 09:53:47 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Language | English |
License | http://onlinelibrary.wiley.com/termsAndConditions#vor 2013 John Wiley & Sons A/S. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4627-9b6d0e040d894a0086b09383986633df0ee4b4e2997cac8cd6cf113fec54fb4a3 |
Notes | istex:097ED56DC1900428C09874195C385E8DA3194D61 ArticleID:LIV12117 ark:/67375/WNG-B9V7494Q-J Bracco Spa - No. BR720c ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 23448378 |
PQID | 1324961173 |
PQPubID | 23479 |
PageCount | 11 |
ParticipantIDs | proquest_miscellaneous_1694973959 proquest_miscellaneous_1324961173 pubmed_primary_23448378 crossref_citationtrail_10_1111_liv_12117 crossref_primary_10_1111_liv_12117 wiley_primary_10_1111_liv_12117_LIV12117 istex_primary_ark_67375_WNG_B9V7494Q_J |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | May 2013 |
PublicationDateYYYYMMDD | 2013-05-01 |
PublicationDate_xml | – month: 05 year: 2013 text: May 2013 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Liver international |
PublicationTitleAlternate | Liver Int |
PublicationYear | 2013 |
Publisher | Blackwell Publishing Ltd |
Publisher_xml | – name: Blackwell Publishing Ltd |
References | Yan AW, Fouts DE, Brandl J, et al. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology 2011; 53: 96-105. Liu H, Zhang S, Yu A, et al. Studies on intestinal permeability of cirrhotic patients by analysis lactulose and mannitol in urine with HPLC/RID/MS. Bioorg Med Chem Lett 2004; 14: 2339-44. Akama F, Nishino R, Makino S, et al. The effect of probiotics on gastric mucosal permeability in humans administered with aspirin. Scand J Gastroenterol 2011; 46: 831-6. Ramos AR, Matte U, Goldani HA, et al. Intestinal permeability assessed by 51Cr-EDTA in rats with CCl4−induced cirrhosis. Arq Gastroenterol 2010; 47: 188-92. Loguercio C, De Simone T, Federico A, et al. Gut-liver axis: a new point of attack to treat chronic liver damage? Am J Gastreoenterol 2002; 97: 2144-6. Guerrero Hernández I, Torre Delgadillo A, Vargas Vorackova F, et al. Intestinal flora, probiotics, and cirrhosis. Ann Hepatol 2008; 7: 120-4. Generoso M, De Rosa M, De Rosa R. Cellobiose and lactulose coupled with mannitol and determined using ion-exchange chromatography with pulsed amperometric detection, are reliable probes for investigation of intestinal permeability. J Chromatogr B 2003; 783: 349-57. Mutlu E, Keshavarzian A, Engen P, et al. Intestinal dysbiosis: a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats. Alcohol Clin Exp Res 2009; 33: 1836-46. Plummer JL, Ossowicz CJ, Whibley C, et al. Influence of intestinal flora on the development of fibrosis and cirrhosis in a rat model. J Gastroenterol Hepatol 2000; 15: 1307-11. Riordan SM, Williams R. Gut flora and hepatic encephalopathy in patients with cirrhosis. N Engl J Med 2010; 362: 1140-2. Morelli L, Garbagna N, Rizzello F, et al. In vivo association to human colon of Lactobacillus paracasei B21060: map from biopsies. Digest Liver Dis 2006; 38: 894-8. Leithner K, Grabovac V, Albrecht K, et al. Permeation studies on freshly excised rat gastric mucosa: influence of pH. Drug Dev Ind Pharm 2011; 37: 518-25. Cariello R, Federico A, Sapone A, et al. Intestinal permeability in patients with chronic liver diseases: its relationship with the aetiology and the entity of liver damage. Dig Liver Dis 2010; 42: 200-4. Jalanka-Tuovinen J, Salonen A, Nikkilä J, et al. Intestinal microbiota in healthy adults: temporal analysis reveals individual and common core and relation to intestinal symptoms. PLoS ONE 2011; 6: e23035. Lee WK, Fujisawa T, Kawamura S, et al. Isolation and identification of clostridia from the intestine of laboratory animals. Lab Anim 1991; 25: 9-15. Federico A, Tuccillo C, Grossi E, et al. The effect of a new symbiotic formulation on plasma levels and peripheral blood mononuclear cell expression of some pro-inflammatory cytokines in patients with ulcerative colitis: a pilot study. Eur Rev Med Pharmacol Sci 2009; 13: 285-93. Almeida J, Galhenage S, Yu J, Kurtovic J, et al. Gut flora and bacterial translocation in chronic liver disease. World J Gastroeneterol 2006; 12: 1493-502. El Bialy SA, Abd El Kader KF, El-Ashmawy MB. Current progress in antifibrotics. Curr Med Chem 2011; 18: 3082-92. Review. Walter J, Tannock GW, Tilsala-Timisjarvi A, et al. Detection and identification of gastrointestinal Lactobacillus species by using denaturing gradient gel electrophoresis and species-specific PCR primers. Appl Environ Microbiol 2000; 66: 297-303. Natarajan SK, Ramamoorthy P, Thomas S, et al. Intestinal mucosal alterations in rats with carbon tetrachloride-induced cirrhosis: changes in glycosylation and luminal bacteria. Hepatology 2006; 43: 837-46. Cesaro C, Tiso A, Del Prete A, et al. Gut microbiota and probiotics in chronic liver diseases. Dig Liver Dis 2011; 43: 431-8. Velayudham A, Dolganiuc A, Ellis M, et al. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 2009; 49: 989-97. Ohland CL, Macnaughton WK. Probiotic bacteria and intestinal epithelial barrier function. Am J Gastrointest Liver Physiol 2010; 298: G807-19. Hurtado I, Santacruz A, Peiró G, et al. Gut microbiota dysbiosis is associated with inflammation and bacterial translocation in mice with CCl4-induced fibrosis. PLoS ONE 2011; 6: e23037. Dastych M, Dastych M Jr, Novotnà H, et al. Lactulose/mannitol test and specificity, sensitivity, and area under curve of intestinal permeability parameters in patients with liver cirrhosis and Crohn's disease. Dig Dis Sci 2008; 53: 2789-92. Miller AM, Horiguchi N, Jeong WI, et al. Molecular mechanisms of alcoholic liver disease: innate immunity and cytokines. Alcohol Clin Exp Res 2011; 35: 787-93. De Foneska A. Kaunitz JD Gastroduodenal mucosal defense. Curr Opin Gastroenterol 2010; 26: 604-10. Chiva M, Soriano G, Rochat I, et al. Effect of Lactobacillus johnsonii La1 and antioxidants on intestinal flora and bacterial translocation in rats with experimental cirrhosis. J Hepatol 2002; 37: 456-62. Nardone G, Compare D, Liguori E, et al. Protective effects of Lactobacillus paracasei F19 in a rat model of oxidative and metabolic hepatic injury. Am J Physiol Gastrointest Liver Physiol 2010; 299: G669-76. Malagon I, Onkenhout W, Klok M, et al. Rhamnose and rhamnitol in dual sugar permeability tests. J Pediatr Gastroenterol Nutr 2006; 43: 265-6. Loguercio C, Federico A, Tuccillo C, et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005; 39: 540-3. Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2008; 49: 1877-87. Furet JP, Quénée P, Tailliez P. Molecular quantification of lactic acid bacteria in fermented milk products using real-time quantitative PCR. Int J Food Microbiol 2004; 97: 197-207. 2002; 37 2006; 12 2002; 97 2006; 38 2000; 66 2011; 53 2008; 7 2010; 362 2011; 35 2011; 37 2008; 53 2011; 6 2011; 18 2009; 49 2009; 33 2009; 13 2010; 42 2004; 97 2010; 26 2010; 47 1991; 25 2000; 15 2006; 43 2004; 14 2008; 49 2010; 299 2010; 298 2011; 43 2011; 46 2005; 39 2003; 783 e_1_2_7_6_1 e_1_2_7_5_1 e_1_2_7_4_1 e_1_2_7_3_1 e_1_2_7_9_1 e_1_2_7_8_1 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_18_1 e_1_2_7_17_1 e_1_2_7_16_1 e_1_2_7_2_1 e_1_2_7_15_1 e_1_2_7_14_1 e_1_2_7_13_1 e_1_2_7_12_1 e_1_2_7_10_1 e_1_2_7_26_1 e_1_2_7_27_1 e_1_2_7_28_1 e_1_2_7_29_1 e_1_2_7_30_1 e_1_2_7_25_1 e_1_2_7_31_1 e_1_2_7_24_1 e_1_2_7_32_1 e_1_2_7_23_1 e_1_2_7_33_1 e_1_2_7_22_1 e_1_2_7_34_1 e_1_2_7_21_1 e_1_2_7_20_1 Federico A (e_1_2_7_11_1) 2009; 13 |
References_xml | – reference: Ramos AR, Matte U, Goldani HA, et al. Intestinal permeability assessed by 51Cr-EDTA in rats with CCl4−induced cirrhosis. Arq Gastroenterol 2010; 47: 188-92. – reference: Miller AM, Horiguchi N, Jeong WI, et al. Molecular mechanisms of alcoholic liver disease: innate immunity and cytokines. Alcohol Clin Exp Res 2011; 35: 787-93. – reference: Akama F, Nishino R, Makino S, et al. The effect of probiotics on gastric mucosal permeability in humans administered with aspirin. Scand J Gastroenterol 2011; 46: 831-6. – reference: Lee WK, Fujisawa T, Kawamura S, et al. Isolation and identification of clostridia from the intestine of laboratory animals. Lab Anim 1991; 25: 9-15. – reference: Federico A, Tuccillo C, Grossi E, et al. The effect of a new symbiotic formulation on plasma levels and peripheral blood mononuclear cell expression of some pro-inflammatory cytokines in patients with ulcerative colitis: a pilot study. Eur Rev Med Pharmacol Sci 2009; 13: 285-93. – reference: Liu H, Zhang S, Yu A, et al. Studies on intestinal permeability of cirrhotic patients by analysis lactulose and mannitol in urine with HPLC/RID/MS. Bioorg Med Chem Lett 2004; 14: 2339-44. – reference: Riordan SM, Williams R. Gut flora and hepatic encephalopathy in patients with cirrhosis. N Engl J Med 2010; 362: 1140-2. – reference: Mutlu E, Keshavarzian A, Engen P, et al. Intestinal dysbiosis: a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats. Alcohol Clin Exp Res 2009; 33: 1836-46. – reference: Loguercio C, Federico A, Tuccillo C, et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005; 39: 540-3. – reference: Malagon I, Onkenhout W, Klok M, et al. Rhamnose and rhamnitol in dual sugar permeability tests. J Pediatr Gastroenterol Nutr 2006; 43: 265-6. – reference: Ohland CL, Macnaughton WK. Probiotic bacteria and intestinal epithelial barrier function. Am J Gastrointest Liver Physiol 2010; 298: G807-19. – reference: Loguercio C, De Simone T, Federico A, et al. Gut-liver axis: a new point of attack to treat chronic liver damage? Am J Gastreoenterol 2002; 97: 2144-6. – reference: Generoso M, De Rosa M, De Rosa R. Cellobiose and lactulose coupled with mannitol and determined using ion-exchange chromatography with pulsed amperometric detection, are reliable probes for investigation of intestinal permeability. J Chromatogr B 2003; 783: 349-57. – reference: Cariello R, Federico A, Sapone A, et al. Intestinal permeability in patients with chronic liver diseases: its relationship with the aetiology and the entity of liver damage. Dig Liver Dis 2010; 42: 200-4. – reference: Dastych M, Dastych M Jr, Novotnà H, et al. Lactulose/mannitol test and specificity, sensitivity, and area under curve of intestinal permeability parameters in patients with liver cirrhosis and Crohn's disease. Dig Dis Sci 2008; 53: 2789-92. – reference: Leithner K, Grabovac V, Albrecht K, et al. Permeation studies on freshly excised rat gastric mucosa: influence of pH. Drug Dev Ind Pharm 2011; 37: 518-25. – reference: Walter J, Tannock GW, Tilsala-Timisjarvi A, et al. Detection and identification of gastrointestinal Lactobacillus species by using denaturing gradient gel electrophoresis and species-specific PCR primers. Appl Environ Microbiol 2000; 66: 297-303. – reference: Jalanka-Tuovinen J, Salonen A, Nikkilä J, et al. Intestinal microbiota in healthy adults: temporal analysis reveals individual and common core and relation to intestinal symptoms. PLoS ONE 2011; 6: e23035. – reference: Velayudham A, Dolganiuc A, Ellis M, et al. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 2009; 49: 989-97. – reference: Morelli L, Garbagna N, Rizzello F, et al. In vivo association to human colon of Lactobacillus paracasei B21060: map from biopsies. Digest Liver Dis 2006; 38: 894-8. – reference: De Foneska A. Kaunitz JD Gastroduodenal mucosal defense. Curr Opin Gastroenterol 2010; 26: 604-10. – reference: El Bialy SA, Abd El Kader KF, El-Ashmawy MB. Current progress in antifibrotics. Curr Med Chem 2011; 18: 3082-92. Review. – reference: Nardone G, Compare D, Liguori E, et al. Protective effects of Lactobacillus paracasei F19 in a rat model of oxidative and metabolic hepatic injury. Am J Physiol Gastrointest Liver Physiol 2010; 299: G669-76. – reference: Plummer JL, Ossowicz CJ, Whibley C, et al. Influence of intestinal flora on the development of fibrosis and cirrhosis in a rat model. J Gastroenterol Hepatol 2000; 15: 1307-11. – reference: Cesaro C, Tiso A, Del Prete A, et al. Gut microbiota and probiotics in chronic liver diseases. Dig Liver Dis 2011; 43: 431-8. – reference: Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2008; 49: 1877-87. – reference: Natarajan SK, Ramamoorthy P, Thomas S, et al. Intestinal mucosal alterations in rats with carbon tetrachloride-induced cirrhosis: changes in glycosylation and luminal bacteria. Hepatology 2006; 43: 837-46. – reference: Yan AW, Fouts DE, Brandl J, et al. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology 2011; 53: 96-105. – reference: Guerrero Hernández I, Torre Delgadillo A, Vargas Vorackova F, et al. Intestinal flora, probiotics, and cirrhosis. Ann Hepatol 2008; 7: 120-4. – reference: Furet JP, Quénée P, Tailliez P. Molecular quantification of lactic acid bacteria in fermented milk products using real-time quantitative PCR. Int J Food Microbiol 2004; 97: 197-207. – reference: Almeida J, Galhenage S, Yu J, Kurtovic J, et al. Gut flora and bacterial translocation in chronic liver disease. World J Gastroeneterol 2006; 12: 1493-502. – reference: Chiva M, Soriano G, Rochat I, et al. Effect of Lactobacillus johnsonii La1 and antioxidants on intestinal flora and bacterial translocation in rats with experimental cirrhosis. J Hepatol 2002; 37: 456-62. – reference: Hurtado I, Santacruz A, Peiró G, et al. Gut microbiota dysbiosis is associated with inflammation and bacterial translocation in mice with CCl4-induced fibrosis. PLoS ONE 2011; 6: e23037. – volume: 25 start-page: 9 year: 1991 end-page: 15 article-title: Isolation and identification of clostridia from the intestine of laboratory animals publication-title: Lab Anim – volume: 298 start-page: G807 year: 2010 end-page: 19 article-title: Probiotic bacteria and intestinal epithelial barrier function publication-title: Am J Gastrointest Liver Physiol – volume: 13 start-page: 285 year: 2009 end-page: 93 article-title: The effect of a new symbiotic formulation on plasma levels and peripheral blood mononuclear cell expression of some pro‐inflammatory cytokines in patients with ulcerative colitis: a pilot study publication-title: Eur Rev Med Pharmacol Sci – volume: 43 start-page: 837 year: 2006 end-page: 46 article-title: Intestinal mucosal alterations in rats with carbon tetrachloride‐induced cirrhosis: changes in glycosylation and luminal bacteria publication-title: Hepatology – volume: 42 start-page: 200 year: 2010 end-page: 4 article-title: Intestinal permeability in patients with chronic liver diseases: its relationship with the aetiology and the entity of liver damage publication-title: Dig Liver Dis – volume: 49 start-page: 989 year: 2009 end-page: 97 article-title: VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet‐induced nonalcoholic steatohepatitis model in mice publication-title: Hepatology – volume: 37 start-page: 456 year: 2002 end-page: 62 article-title: Effect of La1 and antioxidants on intestinal flora and bacterial translocation in rats with experimental cirrhosis publication-title: J Hepatol – volume: 53 start-page: 2789 year: 2008 end-page: 92 article-title: Lactulose/mannitol test and specificity, sensitivity, and area under curve of intestinal permeability parameters in patients with liver cirrhosis and Crohn's disease publication-title: Dig Dis Sci – volume: 37 start-page: 518 year: 2011 end-page: 25 article-title: Permeation studies on freshly excised rat gastric mucosa: influence of pH publication-title: Drug Dev Ind Pharm – volume: 38 start-page: 894 year: 2006 end-page: 8 article-title: association to human colon of B21060: map from biopsies publication-title: Digest Liver Dis – volume: 7 start-page: 120 year: 2008 end-page: 4 article-title: Intestinal flora, probiotics, and cirrhosis publication-title: Ann Hepatol – volume: 35 start-page: 787 year: 2011 end-page: 93 article-title: Molecular mechanisms of alcoholic liver disease: innate immunity and cytokines publication-title: Alcohol Clin Exp Res – volume: 783 start-page: 349 year: 2003 end-page: 57 article-title: Cellobiose and lactulose coupled with mannitol and determined using ion‐exchange chromatography with pulsed amperometric detection, are reliable probes for investigation of intestinal permeability publication-title: J Chromatogr B – volume: 97 start-page: 2144 year: 2002 end-page: 6 article-title: Gut‐liver axis: a new point of attack to treat chronic liver damage? publication-title: Am J Gastreoenterol – volume: 49 start-page: 1877 year: 2008 end-page: 87 article-title: Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease publication-title: Hepatology – volume: 26 start-page: 604 year: 2010 end-page: 10 article-title: Kaunitz JD Gastroduodenal mucosal defense publication-title: Curr Opin Gastroenterol – volume: 6 start-page: e23037 year: 2011 article-title: Gut microbiota dysbiosis is associated with inflammation and bacterial translocation in mice with CCl ‐induced fibrosis publication-title: PLoS ONE – volume: 299 start-page: G669 year: 2010 end-page: 76 article-title: Protective effects of F19 in a rat model of oxidative and metabolic hepatic injury publication-title: Am J Physiol Gastrointest Liver Physiol – volume: 33 start-page: 1836 year: 2009 end-page: 46 article-title: Intestinal dysbiosis: a possible mechanism of alcohol‐induced endotoxemia and alcoholic steatohepatitis in rats publication-title: Alcohol Clin Exp Res – volume: 47 start-page: 188 year: 2010 end-page: 92 article-title: Intestinal permeability assessed by 51Cr‐EDTA in rats with CCl induced cirrhosis publication-title: Arq Gastroenterol – volume: 14 start-page: 2339 year: 2004 end-page: 44 article-title: Studies on intestinal permeability of cirrhotic patients by analysis lactulose and mannitol in urine with HPLC/RID/MS publication-title: Bioorg Med Chem Lett – volume: 39 start-page: 540 year: 2005 end-page: 3 article-title: Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases publication-title: J Clin Gastroenterol – volume: 46 start-page: 831 year: 2011 end-page: 6 article-title: The effect of probiotics on gastric mucosal permeability in humans administered with aspirin publication-title: Scand J Gastroenterol – volume: 362 start-page: 1140 year: 2010 end-page: 2 article-title: Gut flora and hepatic encephalopathy in patients with cirrhosis publication-title: N Engl J Med – volume: 66 start-page: 297 year: 2000 end-page: 303 article-title: Detection and identification of gastrointestinal species by using denaturing gradient gel electrophoresis and species‐specific PCR primers publication-title: Appl Environ Microbiol – volume: 12 start-page: 1493 year: 2006 end-page: 502 article-title: Gut flora and bacterial translocation in chronic liver disease publication-title: World J Gastroeneterol – volume: 43 start-page: 431 year: 2011 end-page: 8 article-title: Gut microbiota and probiotics in chronic liver diseases publication-title: Dig Liver Dis – volume: 53 start-page: 96 year: 2011 end-page: 105 article-title: Enteric dysbiosis associated with a mouse model of alcoholic liver disease publication-title: Hepatology – volume: 18 start-page: 3082 year: 2011 end-page: 92 article-title: Current progress in antifibrotics publication-title: Curr Med Chem – volume: 15 start-page: 1307 year: 2000 end-page: 11 article-title: Influence of intestinal flora on the development of fibrosis and cirrhosis in a rat model publication-title: J Gastroenterol Hepatol – volume: 43 start-page: 265 year: 2006 end-page: 6 article-title: Rhamnose and rhamnitol in dual sugar permeability tests publication-title: J Pediatr Gastroenterol Nutr – volume: 6 start-page: e23035 year: 2011 article-title: Intestinal microbiota in healthy adults: temporal analysis reveals individual and common core and relation to intestinal symptoms publication-title: PLoS ONE – volume: 97 start-page: 197 year: 2004 end-page: 207 article-title: Molecular quantification of lactic acid bacteria in fermented milk products using real‐time quantitative PCR publication-title: Int J Food Microbiol – ident: e_1_2_7_19_1 doi: 10.1016/j.ijfoodmicro.2004.04.020 – ident: e_1_2_7_24_1 doi: 10.1002/hep.24018 – ident: e_1_2_7_15_1 doi: 10.1016/S1570-0232(02)00766-3 – ident: e_1_2_7_25_1 doi: 10.1111/j.1530-0277.2009.01022.x – ident: e_1_2_7_3_1 doi: 10.1016/j.dld.2010.10.015 – ident: e_1_2_7_12_1 doi: 10.1007/s10620-007-0184-8 – ident: e_1_2_7_5_1 doi: 10.3748/wjg.v12.i10.1493 – ident: e_1_2_7_21_1 doi: 10.1097/01.mpg.0000226379.41365.62 – ident: e_1_2_7_9_1 doi: 10.1056/NEJMe1000850 – ident: e_1_2_7_22_1 doi: 10.1590/S0004-28032010000200014 – ident: e_1_2_7_27_1 doi: 10.1046/j.1440-1746.2000.2340.x – ident: e_1_2_7_29_1 doi: 10.1258/002367791780808158 – ident: e_1_2_7_31_1 doi: 10.1371/journal.pone.0023035 – ident: e_1_2_7_4_1 doi: 10.1016/S1665-2681(19)31866-6 – ident: e_1_2_7_13_1 doi: 10.3109/00365521.2011.574730 – ident: e_1_2_7_16_1 doi: 10.1016/j.bmcl.2004.01.107 – ident: e_1_2_7_17_1 doi: 10.1111/j.1530-0277.2010.01399.x – ident: e_1_2_7_28_1 doi: 10.1016/S0168-8278(02)00142-3 – ident: e_1_2_7_6_1 doi: 10.1152/ajpgi.00243.2009 – ident: e_1_2_7_2_1 doi: 10.2174/092986711796391679 – ident: e_1_2_7_26_1 doi: 10.1002/hep.21097 – ident: e_1_2_7_18_1 doi: 10.1128/AEM.66.1.297-303.2000 – ident: e_1_2_7_30_1 doi: 10.1371/journal.pone.0023037 – volume: 13 start-page: 285 year: 2009 ident: e_1_2_7_11_1 article-title: The effect of a new symbiotic formulation on plasma levels and peripheral blood mononuclear cell expression of some pro‐inflammatory cytokines in patients with ulcerative colitis: a pilot study publication-title: Eur Rev Med Pharmacol Sci – ident: e_1_2_7_34_1 doi: 10.1097/MOG.0b013e32833f1222 – ident: e_1_2_7_10_1 doi: 10.1016/j.dld.2006.07.010 – ident: e_1_2_7_8_1 doi: 10.1097/01.mcg.0000165671.25272.0f – ident: e_1_2_7_32_1 doi: 10.1152/ajpgi.00188.2010 – ident: e_1_2_7_14_1 doi: 10.1016/j.dld.2009.05.001 – ident: e_1_2_7_20_1 doi: 10.1002/hep.22711 – ident: e_1_2_7_23_1 doi: 10.1002/hep.22848 – ident: e_1_2_7_33_1 doi: 10.3109/03639045.2010.527348 – ident: e_1_2_7_7_1 doi: 10.1111/j.1572-0241.2002.05942.x |
SSID | ssj0019951 |
Score | 2.1854947 |
Snippet | Aim
Evidence indicates that intestinal microbiota may participate in both the induction and the progression of liver damage. The aim of our research was the... Evidence indicates that intestinal microbiota may participate in both the induction and the progression of liver damage. The aim of our research was the... |
SourceID | proquest pubmed crossref wiley istex |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 687 |
SubjectTerms | Analysis of Variance Animals Carbon Tetrachloride - toxicity Chromatography, High Pressure Liquid Cytokines - metabolism Denaturing Gradient Gel Electrophoresis Feces - chemistry Galactans - pharmacology Gastrointestinal Tract - metabolism Gastrointestinal Tract - microbiology Gene Expression Regulation - drug effects Gene Expression Regulation - immunology Glutamine - pharmacology intestinal microbiota Lactobacillus - metabolism Liver Cirrhosis, Experimental - chemically induced Liver Cirrhosis, Experimental - drug therapy Liver Cirrhosis, Experimental - microbiology Male Permeability - drug effects Probiotics - pharmacology rat liver fibrosis Rats Rats, Wistar Real-Time Polymerase Chain Reaction symbiotic treatment Tumor Necrosis Factor-alpha - blood |
Title | Symbiotic formulation in experimentally induced liver fibrosis in rats: intestinal microbiota as a key point to treat liver damage? |
URI | https://api.istex.fr/ark:/67375/WNG-B9V7494Q-J/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fliv.12117 https://www.ncbi.nlm.nih.gov/pubmed/23448378 https://www.proquest.com/docview/1324961173 https://www.proquest.com/docview/1694973959 |
Volume | 33 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9VAEF5KBfHFS-vleGMVKb6knCSbTVYfpIq1Flvw0tqHwrJXCD0nKU2OeHz1jzuzudBKFfEthNlkdndmdmZ39htCnok8za0WRcQdbt3APER6KpIIqyQlPk3zLMf7znv7fOeA7R5lRyvk5XAXpsOHGDfcUDOCvUYFV7o5p-Sz8htCI8R4kxxztdAh-jRCR-HN4xBsMTz-hzWwRxXCLJ6x5YW16AoO6_fLHM2LfmtYeLZvkOOB5S7f5GRz0epN8-M3NMf_7NNNcr13SOlWJ0G3yIqr1sj6VgXB-HxJN2hIEQ1772vk6l5_Er9Ofn5eznVZQyOKbm9fBIyWFT1fM2C2hDcWpMfSGSaAUA_s1U3ZICHIXvOCIl4FmBnkYV52qFCtoqqhioJ9oac1ENC2piEjvv-KVXMwg69uk4Ptt1_e7ER9QYfIMJ7kkdDcTh2YDVsIpjCaArmAEFkU4Pek1k-dY5o5WCFzo0xhLDc-jlPvTMa8Ziq9Q1arunL3CGXO55brQivDmY6ZygrPp97FHCIgE9sJeT5MrTQ92jkW3ZjJIeoBhmUY6wl5OpKedhAflxFtBPkYKdTZCebE5Zn8uv9OvhaHORPso9ydkCeDAEnQVDx-UZWrF42EuJ8JDt9K_0LDBRN4diom5G4nfeMfk5QF-H_oWpChPzMrP7w_DA_3_530AbmWhEofmMv5kKy2Zwv3CPytVj8OivUL3gomgA |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9QwELZKKwEvHC3HchqEKl5SbRLHjhESKoiylO5KQFv6giJfkaLuJlU3i1he-ePMOIdaVBDiLYnGzjiZGc_Y428IeSZFLKyWacAdLt3Afwj0UEYBVkmK8jgWicDzzuMJHx2w3aPkaIW87M7CNPgQ_YIbaoa316jguCB9RsunxTfERgjFJbKGFb19QPWpB4_Cs8c-3GKYAACzYIsrhHk8fdNzs9EaftjvF7ma5z1XP_XsXCdfO6abjJPjrUWtt8yP3_Ac_3dUN8i11iel240Q3SQrrlwnG9slxOOzJd2kPkvUL7-vk8vjdjN-g_z8vJzpooJGFD3ftg4YLUp6tmzAdAlPLAiQpVPMAaE58FfNizkSgvjNX1CErABLgzzMigYYqlZUzamiYGLoSQUEtK6oT4pve7FqBpbw1S1ysPN2_80oaGs6BIbxSARSczt0YDlsKpnCgApEA6JkmYLrE9t86BzTzMEkKYwyqbHc5GEY584kLNdMxbfJalmV7i6hzOXCcp1qZTjTIVNJmvNh7kIOQZAJ7YA87_5tZlrAc6y7Mc26wAcYzvy3HpCnPelJg_JxEdGmF5CeQp0eY1qcSLIvk3fZa3komGQfs90BedJJUAbKijswqnTVYp5B6M8kh77iv9BwySRun8oBudOIX__GKGa-AgAMzQvRn5nN9t4f-ot7_076mFwZ7Y_34H7y4T65GvnCH5ja-YCs1qcL9xDcr1o_8lr2CySdKps |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKK1VcCrQ8trwMQhWXVHk4dgwHVChLKXTFoy09IEV27EhRd5NVN4tYrvxxZpyHWlQQ4paNJtlJ8s14xh5_Q8gTKSJhtEw8bnHqBr6Dp30ZetglKcyjSMQC9zsfjPjeEds_iU-WyPNuL0zDD9FPuKFlOH-NBj41-TkjHxffkBohEFfICuN-gpDe_dRzR-HWY5dtMVz_h0GwpRXCMp7-0guD0Qq-1--XRZoXA1c38gyvka-dzk3Byen2vNbb2Y_f6Bz_86Guk7U2IqU7DYRukCVbrpONnRKy8cmCblFXI-om39fJ6kG7FL9Bfn5eTHRRwUUU4962CxgtSnq-acB4AWcMwMfQMVaA0BzUq2bFDAUBfLNnFAkrwM-gDpOioYWqFVUzqig4GDqtQIDWFXUl8e1djJqAH3xxkxwNXx--2vPajg5exngoPKm58S34DZNIpjCdAmBAjiwTCHwik_vWMs0sDJEiU1mSGZ7lQRDlNotZrpmKbpHlsirtHUKZzYXhOtEq40wHTMVJzv3cBhxSoCwwA_K0-7Rp1tKdY9eNcdqlPaBw6t71gDzuRacNx8dlQlsOH72EOjvFojgRp19Gb9KX8lgwyT6m-wPyqANQCqaK6y-qtNV8lkLizySHe0V_keGSSVw8lQNyu0Ff_49hxBz_Pzyaw9CflU3fvz12B5v_LvqQrH7YHcLP0bu75Groun5gXec9slyfze19iL1q_cDZ2C-oyClT |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Symbiotic+formulation+in+experimentally+induced+liver+fibrosis+in+rats%3A+intestinal+microbiota+as+a+key+point+to+treat+liver+damage%3F&rft.jtitle=Liver+international&rft.au=D%27Argenio%2C+Giuseppe&rft.au=Cariello%2C+Rita&rft.au=Tuccillo%2C+Concetta&rft.au=Mazzone%2C+Giovanna&rft.date=2013-05-01&rft.issn=1478-3223&rft.eissn=1478-3231&rft.volume=33&rft.issue=5&rft.spage=687&rft.epage=697&rft_id=info:doi/10.1111%2Fliv.12117&rft.externalDBID=10.1111%252Fliv.12117&rft.externalDocID=LIV12117 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1478-3223&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1478-3223&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1478-3223&client=summon |